Patents by Inventor Julie K. Zorman

Julie K. Zorman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9388394
    Abstract: The present invention relates to recombinant C. difficile toxin A (TcdA) and toxin B (TcdB) and binary toxin A (CDTa) proteins comprising specifically defined mutations relative to the native toxin sequence that substantially reduce or eliminate toxicity. The invention also relates to vaccines and immunogenic compositions comprising these recombinant toxins, as well as combinations of these toxins with binary toxin B (CDTb), which are capable of providing protection against C. difficile infection and/or the effects thereof. The invention also relates to methods of inducing an immune response to C. difficile comprising administering the vaccines and immunogenic compositions described herein to a patient. The invention also encompasses methods of expressing recombinant C. difficile toxin A and toxin B and CDTa mutants and CDTb in recombinant expression systems.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: July 12, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jon Henry Heinrichs, Jean-Luc Bodmer, Susan Lynn Secore, Aaron Rudy Goerke, Ivette Caro-Aguilar, Melanie S. Horton, Matthew Ryan Miezeiewski, Julie M. Skinner, Su Wang, Jinfu Xie, Rachel Flora Xoconostle, Julie K. Zorman
  • Publication number: 20150044250
    Abstract: The present invention relates to recombinant C. difficile toxin A (TcdA) and toxin B (TcdB) and binary toxin A (CDTa) proteins comprising specifically defined mutations relative to the native toxin sequence that substantially reduce or eliminate toxicity. The invention also relates to vaccines and immunogenic compositions comprising these recombinant toxins, as well as combinations of these toxins with binary toxin B (CDTb), which are capable of providing protection against C. difficile infection and/or the effects thereof. The invention also relates to methods of inducing an immune response to C. difficile comprising administering the vaccines and immunogenic compositions described herein to a patient. The invention also encompasses methods of expressing recombinant C. difficile toxin A and toxin B and CDTa mutants and CDTb in recombinant expression systems.
    Type: Application
    Filed: January 25, 2013
    Publication date: February 12, 2015
    Applicants: Intervet Inc., Merck Sharp & Dohme Corp.
    Inventors: Jon Henry Heinrichs, Jean-Luc Bodmer, Susan Lynn Secore, Aaron Rudy Goerke, Ivette Caro-Aguilar, Marie-Pierre Gentile, Melanie S. Horton, Matthew Ryan Miezeiewski, Julie M. Skinner, Paulus Jacobus Antonius Sondermeijer, Shyamsundar Subramanian, Karin Huberdina Antonia van der Heijden-Liefkens, Su Wang, Jinfu Xie, Rachel Flora Xoconostle, Julie K. Zorman
  • Publication number: 20130115209
    Abstract: The present invention relates to methods of inducing an immune response to Staphylococcus comprising administering a composition comprising an SA2412 polypeptide from Staphylococcus aureus as well as derivatives or fragments thereof. The present also encompasses methods of treating and/or reducing the likelihood of a Staphylococcus infection by administering a composition comprising an antibody that specifically binds to an SA2412 polypeptide, derivative or fragments thereof. Compositions administered in the methods of the invention can include one or more additional antigens including, but not limited to, IsdB. Compositions used to practice the methods of the invention are also encompassed.
    Type: Application
    Filed: July 11, 2011
    Publication date: May 9, 2013
    Inventors: Tessie B. McNeely, Sharon B. Smith, Julie K. Zorman